ArticleScientific reports2026
Genetic analysis of key players in PI3K signaling cascade of colorectal carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triggering PI3K signaling cascade is most common in human cancers. This study aimed to screen the association of seven SNPs and two hotspot mutations, clinical outcome and therapeutic potential with susceptibility to colorectal carcinoma (CRC). In this case-control study of 495 CRC and 495 controls, seven SNPs were genotyped by ARMS-PCR. The mutant allele frequencies were significantly higher for five SNPs, E542K and E17K but lower for rs6443624 (P = 0.1480) and rs1883965 (P = 0.4105). DNA sequencing results revealed point mutations were more prevalent in CRC. Pairwise linkage disequilibrium analysis was performed and strong LD was observed between rs6443624 and rs10138227 (D' = 0.953, r² = 0.435, LOD = 62.61) among CRC. Pearson's chi-square test showed these variants were associated with CRC risk (P < 0.001). Kaplan Meier analysis revealed that six SNPs (P < 0.005) were strongly associated with clinicopathological parameters and drugs with OS in CRC but not for rs6443624 (P = 0.3). Breslow and Tarone-Ware Test showed significant survival differences but capecitabine revealed the highest survival estimates. Swiss model was used to analyze the changes in protein structure. QMEAND value for E542K is 0.88 ± 0.05 and for E17K is 0.78 ± 0.05 representing high quality structure, however, Ramachandaran structure 97.37% favoured for E542K and 95.23% for E17K. The current study suggests that PI3K pathway variants may be associated with colorectal cancer susceptibility and highlights their potential relevance as candidate biomarkers, pending further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.